Han Oh Park, Ph.D.
Founder and Chief Executive OfficerDr. Han-Oh Park is a biochemist and biotech entrepreneur with an impressive track record in molecular diagnostics and RNA-based therapeutics. He earned his B.S. in Chemistry from Seoul National University and his M.S. and Ph.D. from KAIST, specializing in oligonucleotide and enzymatic synthesis. Before founding Bioneer, he worked as a researcher for seven years in the molecular biology lab of KRIBB (Korea Research Institute of Bioscience and Biotechnology). His strong scientific knowledge drives his vision for translating siRNA into innovative therapeutics.
As the founder, CEO, and Chairman of BIONEER Corporation—established in 1992 as Korea’s first bio-venture company—Dr. Park has led the development and commercialization of DNA/RNA synthesis, PCR, and molecular diagnostics, supplying products and solutions to over 90 countries worldwide. He has consistently driven research and innovation, holding over 600 global patents.
During his tenure at BIONEER, Dr. Park invented the SAMiRNA® platform, a supramolecular siRNA nanoparticle technology designed to address key challenges associated with siRNA therapeutics. Building on this achievement, he founded siRNAgen Therapeutics in 2019 as a spinout from BIONEER to focus on developing next-generation RNAi therapeutics. Under his leadership, siRNAgen has advanced its lead candidate into clinical trials for fibrosis and is expanding its pipeline to address chronic kidney disease, metabolic disorders, immunologic disorders, obesity, oncology, and antiviral therapies.
Dr. Park is an active leader in scientific industry communities, serving as President of the Korea R&D Industry Association, Co-Chair of the Korean Society for Synthetic Biology, Vice President of the Korea Biotechnology Industry Organization, and a member of the National Academy of Engineering of Korea. He has received numerous awards domestically and internationally in recognition of his contributions, including the Gold Tower Order of Industrial Service Merit from the Korean government (2021), the POSCO TJ Park Technology Award from the POSCO TJ Park Foundation (2023), and the FACS Award for Distinguished Contribution to Economic Advancement from the Federation of Asian Chemical Societies (2025).
Through his leadership at BIONEER and siRNAgen, Dr. Park continues to drive innovation, aiming to deliver safe, effective, and accessible solutions for global health challenges.
Jae Mook Choi, Ph.D.
VP of OperationsDr. Jaemook Choi brings over 26+ years of comprehensive expertise in R&D, commercialization, and organizational operations to his role as Vice President of Operations at siRNAgen Therapeutics.
His deep experience in preclinical and clinical drug development make him invaluable in driving assets into and through the clinic.
Since joining, he successfully navigated the flagship asset, SRN-001, into Phase I study in Australia.
With a decade in quality management and 15 years in non-clinical studies and regulatory affairs, Dr. Choi leads early-phase development efforts in the Korea R&D site.
Chun Geun Lee, M.D., Ph.D.
Dr. Chun Geun Lee earned his M.D. and Ph.D. from Hanyang University College of Medicine and completed postdoctoral training in Pulmonary and Critical Care Medicine at Yale University School of Medicine.
Currently a Professor in the Department of Molecular Microbiology and Immunology at Brown University’s Alpert Medical School, he leads cutting-edge research on the molecular mechanisms of lung diseases, including pulmonary fibrosis, emphysema, and asthma.
Dr. Lee has collaborated with Bioneer and siRNAgen Therapeutics on SAMiRNA-based research for lung disease therapies and serves as a key member of our Scientific Advisory Board, guiding the development of innovative RNAi therapeutics.